STAT+: Vertex kidney disease drug scrutinized for infection risk
Ahead of its FDA approval decision on Nov 30, Vertex's kidney disease drug is being heavily scrutinized for infection risk.
We haven't written up this one. STAT News has the full story — the link below goes straight to it.